Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling

Abstract

These data provide context for the ongoing debate about reduction in efavirenz dose to 400 mg during pregnancy and should be interpreted alongside the lower toxicity expected with the lower dose. Additional research is required to investigate genotype-guided dose reduction in pregnant women.

HIV Clinical Updates: New Single-Tablet Regimens

“…31 Emerging data using the lower dose in pregnancy also suggest that adequate exposure is maintained along with reduced toxicities expected. 32,33 Research regarding the use of EFV 400 mg in patients with concomitant tuberculosis is still warranted.…”

Effects of ARVs and HIV on mitochondrial function and immune activation in monocyte derived macrophages in vitro

“…However, since macrophages are known to be more resistant to the effects of ART 108 , it is unclear if these effects will be seen in MDMs. Furthermore, we wanted to understand the effects of these drugs at physiological levels that are similar to the range found in human plasma [230][231][232] . Finally, we…”

“…ARVs were used at physiological concentrations (10µM and 50µM). These concentrations were chosen because they represent the lower and upper range of levels detected in HIV patient plasma samples[230][231][232] . Cells were labelled with Yoyo-1 dye, a DNA stain used to evaluate total cell death.…”